Document is current

Article History

Received: 29 August 2024

Accepted: 18 November 2024

First Online: 17 December 2024

Declarations

:

: Walid Fakhouri, Samuel Ogwu, Ewa Haladyj and Inmaculada de la Torre are employees and minor shareholders of Eli Lilly and Company. Peter C. Taylor reports grants or contract from Galapagos (AlfaSigma) made to University of Oxford; received consulting fees from Abbvie, Biogen, Fresenius, Galapagos (AlfaSigma), Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, UCB, Acelyrin Inc.; received support for attending meetings/travel from Lilly and Galapagis (AlfaSigma); has participated on a Data Safety Monitoring Board/Advisory Board from Immunovant, Sanofi and Moonlake. Bruno Fautrel reports support for medical writing from Lilly; grants or contracts AbbVie, Lilly, MSD, Pfizer; received consulting fees from AbbVie, Amgen, Biogen, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi-Genzyme, SOBI, UCB, Viatris; payment/honoraria from Lilly; support for attending meetings and/or travel from Lilly. Rieke Alten reports consulting fees from Abbvie, BMS, Lilly, Pfizer, Celltrion, UCB, Gilead, Galapagos; received payment or honoraria from Abbvie, BMS; Lilly; Pfizer, Celltrion, UCB, Gilead, Galapagos; received support for attending meetings/travel from Abbvie, BMS, Lilly, Pfizer, Celltrion, UCB, Gilead, Galapagos; has participated on a Data Safety Monitoring Board/Advisory Board from Abbvie, BMS, Lilly, Pfizer, Celltrion, UCB, Gilead, Galapagos. Peter Nash reports consulting fees from Abbvie, Lilly, Pfizer, Amgen, Janssen, Novartis, UCB; payment or honoraria from Abbvie, Lilly, Pfizer, Amgen, Janssen, Novartis, UCB; support for attending meeting/travel from Pfizer, Novartis and stocks/stock options from Pfizer Amgen Lilly GSK Merck. Eugen Feist reports support for medical writing and article processing from Lilly; received grant support to institution from Lilly, Pfizer, Alfasigma; consulting fees from Lilly, Novartis, Abbvie, Sobi, UCB; payment or honoraria from Lilly, Novartis, Abbvie, Sobi, UCB; support for attending meetings/travel from Novartis and Lilly; has participated on a Data Safety Monitoring Board/Advisory Board from Novartis, Abbvie.

: This study was conducted in accordance with Good Pharmacoepidemiology Practice, the principles of the Declaration of Helsinki, and local laws and regulations in the five European countries included in the study. The study protocol was approved by relevant ethics committees in each participating country. All patients provided written informed consent prior to entry to the study. Patients or the public were not involved in the design, conduct, reporting, or dissemination plans of our research.